RESUMEN
Myeloproliferative neoplasms are acquired hematological malignancies, mainly affecting the adult and whose morbidity and mortality stems from haemostasis disorders. The most frequently encountered complications include thrombosis, affecting preferentially the arterial territory, but also atypical locations such as splanchnic vein thrombosis. The pathophysiology of these thromboses is complex and involves different actors: blood cells, endothelium and flow conditions. Numerous studies have been conducted to identify risk factors for thrombosis. To date, only two risk factors have been validated through prospective studies (age over 60 years old, history of thrombotic events) and allow classification of patients as "low risk" and "high risk" as the basis for current treatment recommendations. Haemorrhagic manifestations, less frequent than thrombosis, are mainly related to an alteration of primary haemostasis and are therefore manifested by mucocutaneous bleeding. In these patients, platelet dysfunctions and/or acquired Willebrand syndromes can be found. The pathophysiology of thrombosis and platelet dysfunction during myeloproliferative neoplasms remains to date partially unknown. In this review, we offer to focus on physiopathological mechanisms as well as the latest advances in their understanding.
Asunto(s)
Plaquetas/fisiología , Trastornos Mieloproliferativos/sangre , Trastornos Mieloproliferativos/complicaciones , Trombosis/etiología , Plaquetas/patología , Neoplasias Hematológicas/sangre , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/epidemiología , Neoplasias Hematológicas/fisiopatología , Hemorragia/sangre , Hemorragia/epidemiología , Hemorragia/etiología , Humanos , Trastornos Mieloproliferativos/epidemiología , Trastornos Mieloproliferativos/fisiopatología , Factores de Riesgo , Trombosis/sangre , Trombosis/epidemiología , Trombosis/fisiopatologíaRESUMEN
Acute traumatic coagulopathy (ATC) is an acute and endogenous mechanism triggered by the association of trauma and hemorrhage. Several animal models have been developed, but some major biases have not yet been identified. Our aim was to develop a robust and clinically relevant murine model to study this condition. Anesthetized adult Sprague Dawley rats were randomized into 4 groups: C, control; T, trauma; H, hemorrhage; TH, trauma and hemorrhage (n = 7 each). Trauma consisted of laparotomy associated with four-limb and splenic fractures. Clinical variables, ionograms, arterial and hemostasis blood tests were compared at 0 and 90 min. ATC and un-compensated shock were observed in group TH. In this group, the rise in prothrombin time and activated partial thromboplastin was 29 and 40%, respectively. Shock markers, compensation mechanisms and coagulation pathways were all consistent with human pathophysiology. The absence of confounding factors, such as trauma-related bleeding or dilution due to trans-capillary refill was verified. This ethic, cost effective and bias-controlled model reproduced the specific and endogenous mechanism of ATC and will allow to identify potential targets for therapeutics in case of trauma-related hemorrhage.
Asunto(s)
Trastornos de la Coagulación Sanguínea , Modelos Animales de Enfermedad , Animales , Pruebas de Coagulación Sanguínea , Tiempo de Protrombina , Ratas , Ratas Sprague-DawleyRESUMEN
INTRODUCTION: Factor XIII (FXIII) deficiency is a rare hemorrhagic disorder whose early diagnosis is crucial for appropriate treatment and prophylactic supplementation in cases of severe deficiency. International guidelines recommend a quantitative FXIII activity assay as first-line screening test. FXIII antigen measurement may be performed to establish the subtype of FXIII deficiency (FXIIID) when activity is decreased. METHODS: The aim of this multicenter study was to evaluate the analytical and diagnostic levels of performance of a new latex immunoassay, K-Assay® FXIII reagent from Stago, for first-line measurement of FXIII antigen. Results were compared to those obtained with the Berichrom® FXIII chromogenic assay for measurement of FXIII activity. Of the 147 patient plasma samples, 138 were selected for analysis. RESULTS: The accuracy was very good, with intercenter reproducibility close to 7%. Five groups were defined on FXIII activity level (<5% (n = 5), 5%-30% (n = 23), 30%-60% (n = 17), 60%-120% (n = 69), above 120% (n = 24)), without statistical differences between activity and antigen levels (P value >0.05). Correlation of the K-Assay® with the Berichrom® FXIII activity results was excellent (r = 0.919). Good agreement was established by the Bland and Altman method, with a bias of +9.4% on all samples, and of -1.4% for FXIII levels lower than 30%. One patient with afibrinogenemia showed low levels of Berichrom® FXIII activity but normal antigen level and clot solubility as expected. CONCLUSIONS: The measurement of FXIII antigen using the K-Assay® is a reliable first-line tool for detection of FXIII deficiency when an activity assay is not available.
Asunto(s)
Deficiencia del Factor XIII/sangre , Factor XIII/análisis , Factor XIII/metabolismo , Femenino , Francia , Humanos , MasculinoAsunto(s)
Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Coagulantes/efectos adversos , Factor VIIa/efectos adversos , Deficiencia del Factor XIII/tratamiento farmacológico , Factores Inmunológicos/uso terapéutico , Trombosis/tratamiento farmacológico , Anciano , Inhibidores de Factor de Coagulación Sanguínea/sangre , Femenino , Humanos , Proteínas Recombinantes/efectos adversos , Rituximab , Trombosis/inducido químicamente , Resultado del TratamientoRESUMEN
This report is devoted to the soluble transferrin receptors. We analyzed the comparison between ferritin, soluble transferrin receptors and C reactive protein. The soluble receptor measurement represents a significal advance in assessment of iron status, especially in the diagnosis of iron deficiency associated with inflammation, and in the evaluation of red blood mass during erythroid hyperplasias.